← ANALYST RATINGS · TIPRANKS
Stoke Therapeutics (STOK): analyst forecast and price target
Analyst consensus
Strong Buy7 Buy0 Hold0 Sell
Ratings of 7 analysts in the last 3 months · top analysts only12-month forecast
Based on 7 price targets given in the last 3 months, the average target is $46.71, the highest $60.00, the lowest $39.00. The average is +93.3% from the last price of $24.17.
Analyst ratings 13
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $23.50 → $25.00+6.4% | Hold | +3.4% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $22.50 → $24.00+6.7% | Hold | −0.7% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $23.00 → $25.00+8.7% | Hold | +3.4% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $22.50 → $24.50+8.9% | Hold | +1.4% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $23.50 → $25.00+6.4% | Hold | +3.4% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $22.50 → $24.50+8.9% | Hold | +1.4% | Reiterated | 17.10.26on TipRanks 01:05 | — | |
| Yaron Werber★★★★★★★★★★#117 · hits 59% · avg +28.0% | TD Cowen | $24.74 → $60.00+142.5% | Buy | +148.2% | Reiterated | 13.10.26on TipRanks 08:50 | −6.8%next day +4.5% | ↗ |
| Thomas Shrader★★★★★★★★★★#2198 · hits 39% · avg +6.6% | BTIG | $39.00 | Buy | +61.4% | Reiterated | 12.10.26on TipRanks 09:30 | −2.3%next day −6.8% | ↗ |
| Kevin Strang★★★★★★★★★★#10513 · hits 33% · avg −19.6% | Goldman Sachs | $44.00 | Buy | +82.0% | Reiterated | 05.10.26on TipRanks Oct 6 08:55 | −1.8%next day −4.3% · 5 days −5.0% | ↗ |
| Jessica Fye★★★★★★★★★★#1182 · hits 56% · avg +9.4% | J.P. Morgan | $40.00 | Buy | +65.5% | Initiated | 21.08.26on TipRanks 06:36 | +2.4%next day +0.4% · 5 days −2.5% | ↗ |
| Sumant Kulkarni★★★★★★★★★★#670 · hits 50% · avg +14.2% | Canaccord Genuity | $58.00 | Buy | +140.0% | Reiterated | 12.08.26on TipRanks Aug 13 08:40 | −0.2%next day −5.7% · 5 days +0.6% | ↗ |
| Ananda Ghosh★★★★★★★★★★#1171 · hits 53% · avg +20.8% | H.C. Wainwright | $50.00 | Buy | +106.9% | Reiterated | 04.08.26on TipRanks 11:57 | +5.3%next day +1.0% · 5 days +4.2% | ↗ |
| Joseph Stringer★★★★★★★★★★#293 · hits 48% · avg +24.7% | Needham | $40.00 | Buy | +65.5% | Reiterated | 04.08.26on TipRanks 07:51 | +5.3%next day +1.0% · 5 days +4.2% | ↗ |
| Rudy Li★★★★★★★★★★#235 · hits 63% · avg +76.1% | Wolfe Research | $40.00 | Buy | +65.5% | Reiterated | 03.08.26on TipRanks Aug 4 14:11 | +1.0%next day +5.3% · 5 days +7.0% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $35.00 | Buy | +44.8% | Reiterated | 03.08.26on TipRanks 21:30 | +5.3%next day +1.0% · 5 days +4.2% | ↗ |
| Unknown Analyst | Jefferies | $39.00 → $48.00+23.1% | Buy | +98.6% | Reiterated | 06.07.26on TipRanks Jul 8 21:01 | −1.7%next day +2.3% · 5 days −8.9% | ↗ |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | — | Buy | — | Reiterated | 02.06.26on TipRanks Jun 4 22:20 | −6.0%next day +3.4% · 5 days +5.4% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $38.00 | Buy | +57.2% | Reiterated | 08.05.26on TipRanks 08:40 | −0.5%next day −1.0% · 5 days −8.8% | ↗ |
| Yatin Suneja★★★★★★★★★★#120 · hits 57% · avg +33.0% | Guggenheim | $60.00 | Buy | +148.2% | Reiterated | 07.05.26on TipRanks May 8 07:30 | −1.2%next day −0.5% · 5 days −6.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Stoke Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.40 at a price of $26.00 (+74.6%); now: $45.11 at $24.17 (+86.6%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 2 | 2 | 3 | 3 | 5 |
| Buy | 9 | 6 | 6 | 6 | 5 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.93 (from $-1.05 to $-0.70). Last quarter: $-0.93.
Sales
Next quarter’s sales estimate — $8M (from $2M to $18M). Last quarter: $9M.
Best top-analyst consensus in the sector · Healthcare
About Stoke Therapeutics
- CEO: Ian F. Smith
- Employees: 170
- 45 Wiggins Avenue, Bedford, MA, 01730, US
- www.stoketherapeutics.com
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system. Formerly known as ASOthera Pharmaceuticals, Inc., the company rebranded to Stoke Therapeutics, Inc. in May 2016. Founded in 2014, Stoke Therapeutics, Inc. maintains its headquarters in Bedford, Massachusetts.
Data from the stock’s TipRanks forecast page, read 9 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗